Shares of AC Immune rose by double-digits on news that the company, encouraged by new data, now intends to ask drug ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

The legislation, which is scheduled for a vote Thursday, would send funds directly to health savings accounts paired with ...

An unusual tussle over the availability of funds for Apple Tree’s startups led the firm to seek protection from creditors ...

Casgevy, now a "national priority" drug, helped kids with sickle cell and thalassemia, results which may help toward a label ...

Hemophilia gene therapies arrived a few years ago with blockbuster expectations. But now, one therapy has been pulled from ...

CAR-T cancer therapies now need to succeed in randomized, controlled trials to earn approvals. Elsewhere, a drug from Bristol ...

A high-stakes meeting with wide-ranging public health implications again didn’t result in a vote, as members struggled to ...

Data from the "ADEPT-2" study, which analysts had hoped would arrive before year's end, are now expected sometime in 2026.

The data and AI algorithms within companion apps can help HCPs provide a diagnosis quicker, allowing them to compare their ...

Weeks after being named head of CDER, Pazdur has submitted paperwork to step down at the end of the month, exacerbating ...